Encysive Pharmaceuticals Announces Presentations/Webcasts at C.E. Unterberg Towbin, Rodman & Renshaw, and Cowen & Co. Conference
24 Oktober 2006 - 2:00PM
PR Newswire (US)
HOUSTON, Oct. 24 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals
(NASDAQ:ENCY) today announced that Bruce D. Given, M.D., President
and Chief Executive Officer, will present a corporate overview at
three upcoming health care conferences: the C.E. Unterberg, Towbin
Life Sciences Conference; Rodman & Renshaw 8th Annual
Healthcare Conference; and Cowen & Co. 7th Annual Global Health
Care Conference. Encysive Pharmaceuticals' presentation schedule is
as follows: * C.E. Unterberg, Towbin Life Sciences Conference -
Tuesday, October 31 at 10 a.m. ET at The New York Palace Hotel, New
York City. * Rodman & Renshaw 8th Annual Healthcare Conference
- Monday, November 6 at 8:50 a.m. ET at The New York Palace Hotel.
* Cowen & Co. 7th Annual Global Health Care Conference -
Tuesday, November 7 at 5:30 p.m. GMT (12:30 p.m. ET), The Landmark
Hotel, London. A live webcast of each presentation may be viewed on
the Company's web site at http://www.encysive.com/. A replay will
be available for 30 days following each respective presentation.
About Encysive Pharmaceuticals Encysive Pharmaceuticals Inc. is a
biopharmaceutical company engaged in the discovery, development and
commercialization of novel, synthetic, small molecule compounds to
address unmet medical needs. Our research and development programs
are predominantly focused on the treatment and prevention of
interrelated diseases of the vascular endothelium and exploit our
expertise in the area of the intravascular inflammatory process,
referred to as the inflammatory cascade, and vascular diseases. To
learn more about Encysive Pharmaceuticals please visit our web
site: http://www.encysive.com/. This press release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements are subject to certain risks, trends and uncertainties
that could cause actual results to differ materially from those
projected. Among those risks, trends and uncertainties are our
estimate of the sufficiency of our existing capital resources, our
ability to raise additional capital to fund cash requirements for
future operations, timelines for initiating new clinical trials,
planned announcements of clinical data, the possibility of
obtaining regulatory approval, our ability to manufacture and sell
any products, potential drug candidates, their potential
therapeutic effect, market acceptance or our ability to earn a
profit from sales or licenses of any drug candidate, our ability to
discover new drugs in the future, and our ability to establish
future collaborative arrangements. In particular, careful
consideration should be given to cautionary statements made in the
various reports Encysive, including as Texas Biotechnology
Corporation, has filed with the Securities and Exchange Commission.
Encysive undertakes no duty to update or revise these
forward-looking statements. DATASOURCE: Encysive Pharmaceuticals
CONTACT: Investors, Ann Tanabe, VP, Investor Relations and
Corporate Communications of Encysive Pharmaceuticals,
+1-713-796-8822; or Marcy Strickler of The Trout Group,
+1-212-477-9007 ext. 27; or Media, Dan Budwick of BMC
Communications, +1-212-477-9007 ext. 14, both for Encysive
Pharmaceuticals Web site: http://www.encysive.com/
Copyright
Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Encysive Pharmaceuticals (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Encysive Pharmaceuticals (MM) News-Artikel